Aprea Therapeutics
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3805 Old Easton Rd, Doylestown, Pennsylv...Phone Number
(617) 463-9385Website
www.aprea.comRevenue
<$5 MillionStock Symbol
APREIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Aprea Therapeutics
Aprea Therapeutics, founded in 2001, is a biotechnology research and development company focused on cancer treatment innovation. The company specializes in targeting the ATR pathway to inhibit tumor cells from engaging their DNA damage and response pathways, potentially reducing cancer treatment resistance. Following its acquisition of Atrin Pharmaceuticals in 2022, Aprea has integrated this technology as a core component of its therapeutic strategy. The company operates multiple locations across North America and is publicly traded since 2019.Explore more
Aprea Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aprea Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Aprea Therapeutics had a recent Job posting/layoffs
Aprea Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Aprea Therapeutics is spiking on competitors!
Product Launch: Get notified when Aprea Therapeutics launches new products
Check if Aprea Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Aprea Therapeutics
Earning: See what the market has to say on Aprea Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Aprea Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Aprea Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Aprea Therapeutics
Compare insights from companies similar to Aprea Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aprea Therapeutics
<$5M
1-10
Public
$34M
2001
GS
Gerhard J. SperlVice President, Chemistry, Manufacturing & Controls
Company Profile Activity
Activity Insights
Aprea Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aprea Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aprea Therapeutics.
Aprea Therapeutics financials insights
Gather financial insights about Aprea Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$34M
Aprea Therapeutics Tech Stack
A closer look at the technologies used by Aprea Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Aprea Therapeutics News & Media
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advancesAprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
DOYLESTOWN, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on the ongoing Phase 1 dose escalation ACESOT-1051 trial of its oral WEE1 inhibitor APR-1051.Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” on May 30 at the American Society of ClinicalAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aprea Therapeutics
Sign Up For FreeTo access detailed company insights
Aprea Therapeutics, founded in 2001, is a biotechnology research and development company focused on cancer treatment innovation. The company specializes in targeting the ATR pathway to inhibit tumor cells from engaging their DNA damage and response pathways, potentially reducing cancer treatment resistance. Following its acquisition of Atrin Pharma... Read More
